Heron Neutron Medical Corp.

As of June 30, 2026, Heron Neutron Medical Corp. carries a market capitalization of 64.78B, placing it among publicly traded companies globally. Its enterprise value stands at 55.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Heron Neutron Medical Corp.'s next confirmed earnings release is scheduled for October 22, 2026.

As of June 30, 2026, Heron Neutron Medical Corp. has 158.00M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 6,320.64, and the price-to-book ratio stands at 5.80.

These figures are as of June 30, 2026. The EV/Sales ratio of 5,587.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 55.60B versus a market cap of 64.78B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Heron Neutron Medical Corp. maintains a current ratio of 135.76, meaning it holds 135.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.11, indicating elevated leverage, while an interest coverage ratio of -121.33 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Heron Neutron Medical Corp. posted a negative return on equity (ROE) of -5.30, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -5.14, reflecting losses generated across the asset base. The company generates approximately 100,000.00 in revenue per employee across its workforce of 99.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.28 indicates how many times Heron Neutron Medical Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Heron Neutron Medical Corp.'s stock has declined approximately 39.96% over the past 52 weeks. The 50-day moving average sits at 431.25, while the 200-day moving average is 405.82.

Over the twelve months ended June 30, 2026, Heron Neutron Medical Corp. generated 9.95M in revenue and converted that into -333.20M in net income, yielding earnings per share of -2.17. EBITDA reached -403.56M, while operating income came in at -448.03M.

As of June 30, 2026, Heron Neutron Medical Corp. holds 9.42B in cash and equivalents against 235.86M in total debt, resulting in a net debt position of -536.34M. Total book value stands at 11.16B, with working capital of 9.96B providing operational flexibility.

Heron Neutron Medical Corp. produced -736.23M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -49.32M in capital expenditures, free cash flow totaled -785.55M - equivalent to -5.12 per share.

Over the twelve months ended June 30, 2026, Heron Neutron Medical Corp. posted a gross margin of -319.83, reflecting its pricing power and cost economics. The operating margin of -4,502.83 and net profit margin of -3,348.74 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at 0.00, meaning Heron Neutron Medical Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Heron Neutron Medical Corp. has an Altman Z-Score of 119.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.